Ebola-specific therapeutic antibodies from lab to clinic: The example of ZMapp

In the 1990s, monoclonal antibodies (mAbs) progressed from scientific tools to advanced therapeutics, particularly for the treatment of cancers and autoimmune and inflammatory disorders. In the arena of infectious disease, the inauguration of mAbs as a post-exposure treatment in humans against Ebola...

Celý popis

Uložené v:

Podrobná bibliografia
Vydané v:	Antiviral research Ročník 226; s. 105873
Hlavní autori:	Wong, Gary, Bienes, Kathrina Mae, XIII, Ara, Fausther-Bovendo, Hugues, Kobinger, Gary P.
Médium:	Journal Article
Jazyk:	English
Vydavateľské údaje:	Netherlands Elsevier B.V 01.06.2024
Predmet:	Africa, Western - epidemiology Animals Antibodies, Monoclonal - immunology Antibodies, Monoclonal - therapeutic use Antibodies, Neutralizing - immunology Antibodies, Neutralizing - therapeutic use Antibodies, Viral - immunology Antibodies, Viral - therapeutic use Disease Outbreaks Ebola Virus Ebolavirus - drug effects Ebolavirus - immunology EBOV Hemorrhagic Fever, Ebola - drug therapy Hemorrhagic Fever, Ebola - immunology Humans mAbs Monoclonal antibodies ZMapp Africa, Western Monoclonal antibodies EBOV Ebola Virus ZMapp mAbs
ISSN:	0166-3542, 1872-9096, 1872-9096
On-line prístup:	Získať plný text
Tagy:	Pridať tag Žiadne tagy, Buďte prvý, kto otaguje tento záznam!

Buďte prvý, kto okomentuje tento záznam!